Seelos Therapeutics Doses the First Amyotrophic Lateral Sclerosis Patient with SLS-005 in an Expanded Access Program Psychedelics Investing
Goodness Growth Holdings Announces Amended Credit Facility and Governance Updates Psychedelics Investing
Goodness Growth Holdings Reschedules Release of Fourth Quarter and Full Year 2022 Results to March 31, 2023 Psychedelics Investing
BetterLife's Non-hallucinogenic LSD For Treating Mood Disorders Highlighted in Drug Discovery & Development Article Pharmaceutical Investing
Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human Trials Pharmaceutical Investing
Silo Wellness Eliminates Another CAD$4,440,000 of Debt from Balance Sheet by Disposing of Subsidiary Psychedelics Investing
Goodness Growth Holdings to Report Fourth Quarter and Full Year 2022 Results on March 30, 2023 Psychedelics Investing
Lobe Sciences Ltd. Announces That The Drug Enforcement Administration Has Issued The Initial 2023 Quota Allowing Export Of L-130 Pharmaceutical Investing
Promise of BetterLife's Non-hallucinogenic LSD For Treating Mood Disorders Highlighted in Medical Xpress Article Pharmaceutical Investing
